Howard C Masuoka1, Raj Vuppalanchi1, Ross Deppe1,2, Phelan Bybee1,2, Megan Comerford1, Suthat Liangpunsakul1, Marwan Ghabril1, Naga Chalasani3,4,5. 1. Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. 2. Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN, USA. 3. Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. nchalasa@iu.edu. 4. Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN, USA. nchalasa@iu.edu. 5. David W. Crabb Professor of Medicine, 702 Rotary Building, Suite 225, Indianapolis, IN, 46202, USA. nchalasa@iu.edu.
Abstract
BACKGROUND AND AIM: Hepatocyte apoptosis or necrosis from accumulation of bile salts may play an important role in the disease progression of primary sclerosing cholangitis (PSC). The aim of the current study was to measure serum markers of hepatocyte apoptosis (cytokeratin-18 fragments--K18) and necrosis (high-mobility group protein B1--HMGB1) in adults with PSC and examine the relationship with disease severity. METHODS: We measured serum levels of K18 and HMGB1 in well-phenotyped PSC (N = 37) and 39 control subjects (N = 39). Severity of PSC was assessed biochemically, histologically, and PSC Mayo risk score. Quantification of hepatocyte apoptosis was performed using TUNEL assay. RESULTS: The mean age of the study cohort was 49.7 ± 13.3 years and comprised of 67% men and 93% Caucasian. Serum K18 levels were significantly higher in the PSC patients compared to control (217.4 ± 78.1 vs. 157.0 ± 58.2 U/L, p = 0.001). However, HMGB1 levels were not different between the two groups (5.38 ± 2.99 vs. 6.28 ± 2.85 ng/mL, p = 0.15). Within the PSC group, K18 levels significantly correlated with AST (r = 0.5, p = 0.002), alkaline phosphatase (r = 0.5, p = 0.001), total bilirubin (r = 0.61, p ≤ 0.001), and albumin (r = -0.4, p = 0.02). Serum K18 levels also correlated with the level of apoptosis present on the liver biopsy (r = 0.8, p ≤ 0.001) and Mayo risk score (r = 0.4, p = 0.015). CONCLUSION: Serum K18 but not HMGB1 levels were increased in PSC and associated with severity of underlying liver disease and the degree of hepatocyte apoptosis.
BACKGROUND AND AIM: Hepatocyte apoptosis or necrosis from accumulation of bile salts may play an important role in the disease progression of primary sclerosing cholangitis (PSC). The aim of the current study was to measure serum markers of hepatocyte apoptosis (cytokeratin-18 fragments--K18) and necrosis (high-mobility group protein B1--HMGB1) in adults with PSC and examine the relationship with disease severity. METHODS: We measured serum levels of K18 and HMGB1 in well-phenotyped PSC (N = 37) and 39 control subjects (N = 39). Severity of PSC was assessed biochemically, histologically, and PSCMayo risk score. Quantification of hepatocyte apoptosis was performed using TUNEL assay. RESULTS: The mean age of the study cohort was 49.7 ± 13.3 years and comprised of 67% men and 93% Caucasian. Serum K18 levels were significantly higher in the PSCpatients compared to control (217.4 ± 78.1 vs. 157.0 ± 58.2 U/L, p = 0.001). However, HMGB1 levels were not different between the two groups (5.38 ± 2.99 vs. 6.28 ± 2.85 ng/mL, p = 0.15). Within the PSC group, K18 levels significantly correlated with AST (r = 0.5, p = 0.002), alkaline phosphatase (r = 0.5, p = 0.001), total bilirubin (r = 0.61, p ≤ 0.001), and albumin (r = -0.4, p = 0.02). Serum K18 levels also correlated with the level of apoptosis present on the liver biopsy (r = 0.8, p ≤ 0.001) and Mayo risk score (r = 0.4, p = 0.015). CONCLUSION: Serum K18 but not HMGB1 levels were increased in PSC and associated with severity of underlying liver disease and the degree of hepatocyte apoptosis.
Authors: Gerald Denk; Ahmed-Jawid Omary; Florian Paul Reiter; Simon Hohenester; Ralf Wimmer; Stefan Holdenrieder; Christian Rust Journal: Hepatol Res Date: 2014-02-28 Impact factor: 4.288
Authors: Raj Vuppalanchi; Ajay K Jain; Ross Deppe; Katherine Yates; Megan Comerford; Howard C Masuoka; Brent A Neuschwander-Tetri; Rohit Loomba; Elizabeth M Brunt; David E Kleiner; Jean P Molleston; Jeffrey B Schwimmer; Joel E Lavine; James Tonascia; Naga Chalasani Journal: Clin Gastroenterol Hepatol Date: 2014-05-17 Impact factor: 11.382
Authors: W R Kim; T M Therneau; R H Wiesner; J J Poterucha; J T Benson; M Malinchoc; N F LaRusso; K D Lindor; E R Dickson Journal: Mayo Clin Proc Date: 2000-07 Impact factor: 7.616
Authors: Stefania Gardella; Cristina Andrei; Denise Ferrera; Lavinia V Lotti; Maria R Torrisi; Marco E Bianchi; Anna Rubartelli Journal: EMBO Rep Date: 2002-09-13 Impact factor: 8.807
Authors: Ariel E Feldstein; Anna Wieckowska; A Rocio Lopez; Yao-Chang Liu; Nizar N Zein; Arthur J McCullough Journal: Hepatology Date: 2009-10 Impact factor: 17.425
Authors: Yusuf Yilmaz; Enver Dolar; Engin Ulukaya; Semra Akgoz; Murat Keskin; Murat Kiyici; Omer Yerci; Arzu Yilmaztepe Oral; Cuma Bulent Gul; Selim Gurel; Selim Giray Nak; Macit Gulten Journal: Med Sci Monit Date: 2009-04
Authors: Katherine P Yates; Ross Deppe; Megan Comerford; Howard Masuoka; Oscar W Cummings; James Tonascia; Naga Chalasani; Raj Vuppalanchi Journal: PLoS One Date: 2017-11-02 Impact factor: 3.240